A German company that oversees clinical trials for new drugs and medical devices has opened an office on the South Side, its first in North America and a vote of confidence in the region’s potential in the field.
Mannheim-based Scope International AG becomes only the second company of its kind doing business in Pittsburgh, according to Alethea Wieland, president and CEO of Scope International USA Inc. The choice of Pittsburgh — which wasn’t originally where Scope considered setting up shop — reflects the city’s medical research capabilities and fledgling life sciences industry, she said.
“Pittsburgh is an emerging market for life sciences,” Ms. Wieland said. “We have the expertise here.”
Scope is a contract research organization that is hired to conduct clinical trials and oversee regulatory submissions for pharmaceutical, biotechnology and medical device companies. The company’s only local competitor is South Side-based Novum Pharmaceutical Research Services, Ms. Wieland said.
By comparison, the Philadelphia area has hundreds of contract research organizations, part of an industry infrastructure that serves numerous drug companies in eastern Pennsylvania and New Jersey.
Scope, which is privately held, was founded in 2000 and has 250 employees covering more than 30 countries. In Pittsburgh, the company plans to double its payroll to 18 full- and part-time employees by this fall.
Scope’s choice of cities comes as the University of Pittsburgh ramps up its drug development capabilities, and within five months of an innovative agreement between Pitt and biopharmaceutical giant Shire.
Under the agreement, Shire, a $6.4 billion company based in Dublin, will partner with Pitt researchers to develop treatments for rare diseases, the sort of collaboration advocated by chancellor Patrick Gallagher as a “priority” for the university.
“For decades, Pitt has been a leading research university, and, as we move into our next phase, finding external partnerships with companies like Shire is critical for our future and a priority at Pitt,” Mr. Gallagher said in a prepared statement when the deal was announced in November.
The region’s health services sector employed 107,531 people at 2,820 companies in 2013, the latest available figures, according to the Pittsburgh Technology Council, an Oakland-based advocacy group.
In addition the region had 10,771 graduate students in science, engineering and health care in 2012, the PTC found — a three-year high.
For its part, Scope coordinates trials to prove the safety and effectiveness of drugs and medical devices through contracts with university researchers, pharmaceutical companies and other clients.
Scope has taken about 4,000 square feet of office space on Sidney Street on the South Side, with the potential to add another 6,500 square feet if needed.
The professional services company initially planned to open its first North American office in Richmond, Va.
But during her job interview at Scope, Ms. Wieland pitched Pittsburgh as a better place to open an office because of its low cost of living, depth of university research and proximity to other life science hubs, including Cleveland, Buffalo and Rochester, N.Y. A follow-up presentation with officials from the Allegheny Conference and other economic development organizations sealed the deal, she said.
“I am thrilled that Scope has come to Pittsburgh to serve our life sciences community,” said Dietrich Stephan, a veteran entrepreneur and chair of the university’s Department of Human Genetics at the Graduate School of Public Health. “There’s lots of great opportunities to do drug development in Pittsburgh.”
Coincidentally, Scope’s offices are just a few blocks away from Noveome Biotherapeutics Inc., a clinical stage company formerly known as Stemnion Inc., which announced last week that its product, dubbed ST266, had finished the U.S. Food and Drug Administration’s phase-one trials for safety in skin, oral and eye applications.
Enrollment of patients in phase-two trials were planned for the first quarter as the company rapidly moves into development from research, according the company.
Before working at Scope, Ms. Wieland was director of clinical affairs at South Side-based Helomics, a personalized medicine company; manager, business development at CECity, a Homestead-based health care software company; and a regulatory specialist at the National Surgical Adjuvant Breast/Bowel Project, which is based at Allegheny General Hospital on the North Side.
Kris B. Mamula:kmamula@post-gazette.com or 412-263-1699






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.